August 2009
Pharmaceutical Representative;Aug2009, Vol. 39 Issue 8, p11
The article reports on the approval of the U.S. Food and Drug Administration (FDA) on the use of Fanapt tablets to treat adults with schizophrenia and chronic disabling brain disorder. The drug will bear a box warning against off-label use for treatment of older people with behavioral problems and dementia-related psychosis. The drug was developed by Canadian company Patheon Inc. for Vanda Pharmaceuticals Inc.


Related Articles

  • Fanapt.  // Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Fanapt (Iloperidone) from Vanda Pharmaceuticals Inc. to treat schizophrenia. It notes that the drug was first developed by Hoechst and licensed to Titan Pharmaceuticals. The company plans to make the drug...

  • Vanda Submits NDA For Iloperidone.  // Bioworld Week;10/1/2007, Vol. 15 Issue 40, p6 

    The article reports that Vanda Pharmaceuticals Inc. has submitted a new drug application (NDA) following up the successful Phase III study in 2006 for schizophrenia tablet iloperidone to the Food and Drug Administration (FDA) on September 28, 2007 in Rockville, Maryland. The company is using a...

  • New atypical antipsychotic approved. Traynor, Kate // American Journal of Health-System Pharmacy;6/15/2009, Vol. 66 Issue 12, p1063 

    The article reports on the approval of the Food and Drug Administration (FDA) to release Vanda Pharmaceuticals Inc.'s Fanapt in the U.S. market. The approval for atypical antipsychotic drug iloperidone aims to minimize the risk of treatment regimen with the dosage of iloperidone to resume...

  • Iloperidone: An atypical antipsychotic. Tanzi, Maria G. // Pharmacy Today;Jul2009, Vol. 15 Issue 7, p29 

    The article reports on the approval of the iloperidone drug for acute treatment of schizophrenia by the U.S. Food and Drug Administration (FDA). It states that the drug, developed by Vanda Pharmaceuticals Inc., has a low affinity for histamine receptors, which may lower the risk of somnolence....

  • Rights to Two Medications Are Obtained By Novartis.  // Chain Drug Review;10/26/2009, Vol. 31 Issue 18, p67 

    The article offers news briefs related to drug approval in the U.S. Novartis Pharma AG has dealt with Vanda Pharmaceuticals Inc. to sell Fanapt medication oral therapy to treat schizophrenia. Media Pharmaceuticals Inc. has received approval from Food and Drug Administration (FDA) for Astepro...

  • Rhythm, no blues: Vanda sleep therapy wins FDA clearance. Osborne, Randy // BioWorld Today;2/3/2014, Vol. 25 Issue 22, p1 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to Vanda Pharmaceutical Inc. for its Hetlioz, a selective melatonin receptor agonist for non-24-hour wake-sleep disorder. It mentions the schedule of the launch of the drug in the market and provides...

  • Vanda Shares Surge 626% on FDA Approval of Fanapt.  // Bioworld Week;5/11/2009, Vol. 17 Issue 19, p1 

    The article reports on the 626% increase of shares of Vanda Pharmaceuticals Inc. in the U.S. It is due to the U.S. Food and Drug Administration's approval of the Vanda's antipsychotic drug Fanapt. It indicates that the drug has a negative effect in triglycerides or fatty acids and placebo- like...

  • FDA accepts Vanda's iloperidone NDA resubmission.  // PharmaWatch: Biotechnology;Jan2009, Vol. 8 Issue 1, p11 

    The article reports that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the iloperidone new drug application by Vanda Pharmaceuticals Inc. It is noted that the resubmission was a complete response to the not approvable action letter that Vanda received on July 25,...

  • FDA Not-Approvable Letter Sinks Vanda.  // Bioworld Week;8/4/2008, Vol. 16 Issue 31, p3 

    The article reports on the not-approvable letter issued by the United States Food and Drug Administration (FDA) concerning the proposal of Vanda Pharmaceuticals Inc. to approve its iloperidone drug. The agency stresses that based on the clinical trials conducted by the company to assess the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics